Market Size and Growth
The Global Neuroendocrine Tumor Treatment Market size reached USD 2.7 Billion in 2025 and is projected to reach USD 5.8 Billion by 2033, growing at a CAGR of 8.0% during the forecast period (2026-2033). The key market players are adopting various strategies such as mergers and acquisitions, product approvals, and agreements to increase product reach and strengthen their product portfolios, in order to enter or expand their business offerings and competitiveness in the neuroendocrine tumor treatment market.
For instance, in June 2021, The National Medical Products Administration of China ("NMPA") authorized saracatinib for drug registration as a treatment for advanced pancreatic neuroendocrine tumors, according to a statement from HUTCHMED (China) Limited ("HUTCHMED") ("pNETs").
The neuroendocrine tumor is a rare tumor that arises from the specialized body cells called neuroendocrine cells. It may occur anywhere in the body but mostly in the pancreas, digestive tract, lungs, rectum, and appendix. The neuroendocrine tumor can be either benign or malignant.
The growing cases of neuroendocrine tumors, increasing product approvals, growing research, and increasing awareness are the factors driving global neuroendocrine tumor treatment market growth in the forecast period.
Market Scope
| Metrics | Details |
| Market CAGR | 8.0% |
| Segments Covered | Therapy Type, Indication, Route of Administration, End User, and Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Therapy Type Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis key Insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
For More Insights: Request Sample
Market Dynamics
The increasing product approvals are driving the global neuroendocrine tumor treatment market growth.
The increasing product approvals are driving the global neuroendocrine tumor treatment market growth. For instance, in September 2022, Eli Lilly and Company received the U.S. Food and Drug Administration (FDA) approval for its Retevmo (selpercatinib, 40 mg & 80 mg capsules) indicated for the treatment of locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene fusion that has progressed on or following prior systemic treatment in adults or in patients who do not have an adequate alternative therapy choice. This indication is authorized under accelerated clearance established on the overall response rate (ORR) and duration of response (DOR). Persisted clearance for this indication may be contingent upon assurance and depiction of clinical usefulness in the confirming trial.
The treatment-induced side effects are expected to hamper the global neuroendocrine tumor treatment market growth.
The side effects caused by the neuroendocrine treatment are expected to hamper the global neuroendocrine tumor treatment market growth during the forecast period. The possible side effects of neuroendocrine tumor treatment include high blood sugars, the development of gallstones, and mild digestive system upset, such as bloating and nausea.
Market Segmentation Analysis
The global neuroendocrine tumor treatment market is segmented based on therapy type, indication, route of administration, end-user, and region.
The injectable segment is expected to hold a dominant position in the market over the forecast period.
The increasing research investments by various key market payers in developing new drug delivery options are estimated to boost the injectable segment growth and hold over 68.5% of the total global neuroendocrine tumor treatment market over the forecast period.
For instance, in March 2022, Ipsen a multinational, mid-sized biopharmaceutical corporation concentrated on transformative treatments in oncology, a rare disorder, and neuroscience declared its investment in a new state-of-the-art electronic autoinjector for Somatuline Autogel / Somatuline Depot (lanreotide) developed to enhance the patient experience for individuals living with carcinoid syndrome, acromegaly, or gastroenteropancreatic neuroendocrine tumors.
Market Geographical Share
North America Holds the Largest Share of the Global Neuroendocrine Tumor Treatment Market.
North America is estimated to hold above 39.4% of the total owing to the increasing prevalence of neuroendocrine cancer in this region. For instance, according to the American Society of Clinical Oncology (ASCO), about 8,000 adults in the United States are diagnosed with a GI tract NET yearly. It is estimated that over 12,000 individuals in the US are diagnosed with NET annually, and about 175,000 individuals live with it.
Market Companies
The major global players in the market include Pfizer, Inc., Ipsen Pharmaceuticals, Novartis, AVEO Pharmaceuticals, Inc., Eli Lilly & Company, CK Hutchison Holdings (HUTCHMED), C.H. Boehringer Sohn Ag & Co. KG (Boehringer Ingelheim International GmbH), Lantheus Holdings, Inc., Merck & Co., Inc. and Sanofi among others.
Recent Developments
April 2026: Expansion of PRRT competition and regulatory momentum
In April 2026, regulatory progress strengthened the peptide receptor radionuclide therapy (PRRT) segment. The FDA granted tentative approval to PNT2003, a Lutetium-based therapy considered radioequivalent to LUTATHERA®, which could broaden treatment access once patent barriers ease. This reflects increasing competition and expansion in radiopharmaceutical NET therapies.
April 2026: Market expansion supported by radiopharmaceutical supply chain scaling
In April 2026, market research highlighted growing adoption of PRRT therapies driven by improved isotope supply chains (especially Lutetium-177 production capacity). This has reduced previous treatment bottlenecks and is enabling wider hospital adoption of targeted radiotherapy for advanced NET cases.
March 2026: Breakthrough radiopharmaceutical and CAR-T pipeline progress
Clinical trial updates in March 2026 highlighted strong momentum in advanced NET therapies, especially radiopharmaceutical treatments and CAR-T cell therapy. A Phase 3 study of ITM-11 (177Lu-edotreotide) showed significantly improved progression-free survival compared with everolimus in pancreatic NET patients. Early-stage CAR-T programs targeting gastrointestinal NETs also advanced to higher dose levels, signaling growing interest in cell-based immunotherapy approaches for NETs.
March 2026: Growth driven by targeted and immunotherapy innovation
Industry analysis released in March 2026 showed the NET treatment market continuing steady growth due to expanding targeted therapy and immunotherapy pipelines, including drugs from major pharmaceutical developers. Increasing clinical trials and investments in novel agents are accelerating treatment diversification beyond somatostatin analogs.
Why Purchase the Report?
- To visualize the global neuroendocrine tumor treatment market segmentation based on therapy type, indication, route of administration, end-user, and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of neuroendocrine tumor treatment market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The global neuroendocrine tumor treatment market report would provide approximately 53 tables, 54 figures, and 195 Pages.
Target Audience
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
